Characteristics of Sexual Dysfunction in Patients With Lung Cancer
- Conditions
- Lung CancerSexual Dysfunction
- Interventions
- Drug: Systemic oncological treatment
- Registration Number
- NCT06018376
- Lead Sponsor
- Fundación GECP
- Brief Summary
The general objective of this observational study is identify and describe the type, frequency, and severity of sexual dysfunction in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population. The recruitment will be carried out from July 2023 and will be carried out until December 2023, the analysis of the information will be carried out from January to March 2024.
- Detailed Description
It is planned to develop a study with a larger number of patients with lung cancer, including the population of Spain and Latin American countries to obtain a sample of more diverse and heterogeneous characteristics, with clinical, cultural, and sociodemographic differences. This will make it possible to obtain better and greater data and therefore define the clinical and treatment factors significantly associated with DS in these individuals and obtain a more complete vision of the reality of the problem.
The results of this research will make it possible to carry out interventions specifically directed at this population and to modify the oncological follow-up guidelines currently in force. Likewise, the information collected will serve as the basis for generating new protocols for a multidisciplinary approach, including the participation of psychology and specialists in urology, gynecology, and psychiatry.
The general objective of this observational study is identify and describe the type, frequency, and severity of sexual dysfunction in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population. The recruitment will be carried out from July 2023 and will be carried out until December 2023, the analysis of the information will be carried out from January to March 2024.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 553
- Age greater than or equal to 18 years and less than or equal to 70 years.
- Diagnosis of lung cancer stages IB to IV.
- Having received systemic oncological treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months with stable tumor disease or partial or complete response in images.
- ECOG ≤ 2
- Patients with comorbidities (renal failure, cardiovascular diseases or similar) not controlled with corresponding medical management.
- Individuals with physical disability or cognitive impairment that prevents them from completing the electronic data collection form.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Observational Study Group Systemic oncological treatment * Age greater than or equal to 18 years and less than or equal to 70 years. * Diagnosis of lung cancer stages IB to IV. * Having received systemic oncological treatment for at least 3 months * ECOG ≤ 2
- Primary Outcome Measures
Name Time Method Number of Participants with different type, frequency and severity of sexual dysfunction From inclusion up to 3 months Identify and describe the type, frequency, and severity of DS in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population.
- Secondary Outcome Measures
Name Time Method Number of participants with risk factors for the development and severity of sexual dysfunction. From inclusion up to 3 months Analysis of risk factors for the development and severity of sexual dysfunction described in the clinical history and study questionnaires.
Number of participants with sexual dysfunction according to different characteristics From inclusion up to 3 months To characterize the differences in sexual dysfunction in patients with lung cancer according to age, sociodemographic characteristics, region of residence, and type of cancer treatment.
Trial Locations
- Locations (29)
Instituto Alexander Flemming
🇦🇷Buenos Aires, Argentina
Oncomedica, IMAT
🇨🇴Montería, Monteria, Colombia
Clínica Universitaria Colombia
🇨🇴Bogotá, Colombia
Clinica del Occidente
🇨🇴Cali, Colombia
Hematooncologos SA
🇨🇴Cali, Colombia
Clínica de Medellín
🇨🇴Medellín, Colombia
ALIADAS Instituto Nacional de Enfermedades Neoplasicas
🇵🇪Surquillo, Peru
Centro Hospitalar do Porto
🇵🇹Porto, Portugal
Hospital General de Elche
🇪🇸Elche, Alicante, Spain
ICO Badalona, Hospital Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
Scroll for more (19 remaining)Instituto Alexander Flemming🇦🇷Buenos Aires, Argentina